NOV 15, 2018 2:17 PM PST

Anti-inflammatory Drug Works Like an Inhibitor

WRITTEN BY: Nouran Amin

At Karolinska Institutet in Sweden, a team of scientists from multiple disciplines have worked together to develop an inflammation inhibitor.

Credit: The Scientist

The new anti-inflammatory drug molecule possess a unique mechanism of action. Essentially, the drug works by inhibiting a certain protein, called OGG1, which is studied to repair DNA was found to cause a reduction in the signals that trigger an inflammation.

The inhibitor works by blocking the release of inflammatory proteins, such as TNF alpha. During investigations on mice with acute pulmonary disease, the drug was found to dampen the inflammation.

Learn more about inflammatory responses:

In collaboration with the University of Texas Medical Branch, Uppsala University and Stockholm University--results of the findings are described in a publication in Science.

"We've developed a new drug molecule that inhibits inflammation," explains co-leader of the study, Professor Thomas Helleday, at the Department of Oncology-Pathology, Karolinska Institutet, Sweden. "It acts on a protein that we believe is a general mechanism for how inflammation arises in cells."

Discovery of the anti-inflammatory drug was the product of a long-term investigation on the mechanisms behind DNA repair—with the objective of fighting cancer by targeting a tumors cell’s DNA. Such research has resulted in several breakthrough drug discoveries including PARP inhibitors for the treatment of congenital breast and ovarian cancer.

Researchers were originally investigating the development of a new molecule that inhibits the enzyme, OGG1, which was found to be responsible for oxygen damage to DNA—that’s when they discovered that the molecule also dampened inflammation.

The result concluded that OGG1, apart from repairing DNA, triggers inflammation—making its inhibition critical in the treatment for inflammatory diseases.

"This discovery could give rise to a new treatment for a very serious condition," says Professor Helleday. "We'll now be developing our OGG1 inhibitor and examining whether it can lead to new treatments for inflammatory diseases in order to cure or relieve diseases such as sepsis, COPD and severe asthma."

Source: Science Magazine

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
MAY 21, 2020
Cancer
MAY 21, 2020
A New Player in the Regulation of Cancer's Microenvironment
Breast cancer is one of the most common cancers in the world.  Triple-negative breast cancer (TNBC) is a sub-type o ...
MAY 21, 2020
Drug Discovery & Development
MAY 21, 2020
Molecular 'Switch' Makes Autoimmune Drugs Fight Cancer
Researchers from the Antibody and Vaccine Group at the University of Southampton, England, have identified a way to repu ...
MAY 23, 2020
Chemistry & Physics
MAY 23, 2020
Improving the understanding of GPCRs functioning
New research reported in Current Opinion in Structural Biology combines structural and spectroscopic approaches to garne ...
MAY 25, 2020
Cancer
MAY 25, 2020
Using Transcription Factors to Predict Bladder Cancer Prognosis
Bladder cancer is a rare form of cancer, with a relatively high recovery rate. Recurrence is still an issue; however, wi ...
JUN 07, 2020
Drug Discovery & Development
JUN 07, 2020
Repurposing An Antibiotic To Defeat a Deadly Superbug
A recent study published in Nature Microbiology describes how an old antibiotic used for Tuberculosis can be powerful tr ...
JUN 29, 2020
Drug Discovery & Development
JUN 29, 2020
Staring into Deep Red Light Improves Eyesight
Researchers from UCL have found that staring into a deep red light for just three minutes per day can significantly impr ...
Loading Comments...